Actinogen Medical progresses in XanaMIA Phase 2b/3 trial for Alzheimer’s disease
Actinogen Medical Limited (ASX: ACW) has announced a major milestone in its ongoing XanaMIA Phase 2b/3 clinical trial, aimed at treating biomarker-positive mild to moderate ... Read More
Cassava Sciences stock craters after Alzheimer’s drug trial flops in critical phase
Cassava Sciences, Inc., a clinical-stage biotechnology company, revealed a significant setback in its pursuit of an effective treatment for Alzheimer’s disease. The company reported that ... Read More
AbbVie makes bold move in Alzheimer’s market with $1.4bn Aliada buyout—Is it a gamble?
AbbVie, the renowned American biopharmaceutical giant, is set to acquire Aliada Therapeutics for a staggering $1.4 billion. The acquisition grants AbbVie control over Aliada’s promising ... Read More
Actinogen Medical makes bold A$11.1m move to boost Alzheimer’s drug trial
Actinogen Medical has raised 11.1 million AUD in a significant capital raise led by its CEO, Dr. Steven Gourlay, who personally invested 1 million AUD. ... Read More
Athira Pharma stock nosedives after Alzheimer’s drug trial results disappoint
Athira Pharma's stock plunged by 75% after the company announced that its Phase 2/3 LIFT-AD clinical trial for its experimental Alzheimer’s drug, fosgonimeton, failed to ... Read More
Athira Pharma completes patient dosing in Phase 2/3 trial of fosgonimeton in AD
Athira Pharma, Inc. (NASDAQ: ATHA), a prominent biopharmaceutical company specializing in neurodegenerative diseases, has announced the completion of patient dosing in the Phase 2/3 LIFT-AD ... Read More
AriBio gets exclusive marketing rights in China for Alzheimer’s candidate AR1001 in $770m deal
In a significant stride towards addressing early Alzheimer’s disease, AriBio Co., Ltd. (AriBio) has announced an exclusive agreement to market AR1001, a pioneering investigational drug, ... Read More
Eisai invests $15m in C₂N Diagnostics to advance Alzheimer’s disease diagnostics
In a significant move for the field of brain health diagnostics, C₂N Diagnostics, LLC, a pioneer in developing advanced diagnostic solutions for Alzheimer's disease, has ... Read More
Alpha Cognition advances Alzheimer’s treatment with new patent filing
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a pioneering biopharmaceutical company in the development of novel treatments for neurodegenerative diseases, has recently taken a significant ... Read More
Schroders Capital invests in Neurona Therapeutics to advance neural cell therapies
In a significant development for the life sciences sector, Schroders Capital Global Innovation Trust plc has announced a strategic investment of $1.6 million (£1.3 million) ... Read More